Authors : Dr. M. J. Priyadarshini; Dr. B. Shanthi; Dr. V. Kalaiselvi; Dr. K. Sumathi

Volume/Issue : Volume 11 - 2026, Issue 9 - September

---

Google Scholar : https://tinyurl.com/3yzfv3aw

DOI : https://doi.org/10.38124/ijisrt/26sep443

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : Background: Atypical chronic myeloid leukaemia (aCML), BCR-ABL1-negative, is a rare clonal myelodysplastic/myeloproliferative neoplasm accounting for roughly 1–2% of BCR-ABL1-positive CML cases. It typically affects patients in the seventh–eighth decade, presenting with marked leukocytosis, dysgranulopoiesis, organomegaly, and variable cytopenias in the absence of the BCR-ABL1 fusion.

Keywords : Atypical Chronic Myeloid Leukaemia; BCR-ABL1-Negative; Myelodysplastic/Myeloproliferative Neoplasm; Hyperleukocytosis; Hyperuricemia.

References :

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
2. WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours. 5th ed. Vol. 11. Lyon: International Agency for Research on Cancer; 2024. Section: Myelodysplastic/myeloproliferative neoplasms, p.102–104.
3. Tefferi A, Gilliland DG. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol. 2006;19(3):365–385.
4. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18–24.
5. Belkhair J, Raissi A, Elyahyaoui H, Ait Ameur M, Chakour M. Atypical chronic myeloid leukemia BCR-ABL1 negative: a case report and literature review. Leuk Res Rep. 2019;12:100172.
6. Diamantopoulos PT, Viniou NA. Atypical chronic myelogenous leukemia, BCR-ABL1 negative: diagnostic criteria and treatment approaches. Front Oncol. 2021;11:722507.
7. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122–127.
8. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev. 2019;33:74–81.
9. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–1790.
10. Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122(10):1707–1711.
11. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27(9):1870–1873.
12. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia. 2013;27(6):1401–1403.
13. Elliott MA, Dewald GW, Tefferi A, Hanson CA. Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia. 2001;15(1):35–40.
14. Cazzola M, Malcovati L, Invernizzi R. Myelodysplastic/myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2011;2011(1):264–272.
15. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, for the CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. J Clin Epidemiol. 2014;67(1):46–51.
16. Riley DS, Barber MS, Kienle GS, Aronson JK, von Schön-Angerer T, Tugwell P, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017;89:218–235.
17. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.
18. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854.
19. Menakuru SR, Priscu A, Beirat A, Dhillon VS, Salih A, Emran J. Hyperleukocytosis and pseudohyperkalemia in a patient with severe SARS-COVID-19 unmasks chronic lymphocytic leukemia. Cureus. 2021;13(12):e20826.
20. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER Hematopoietic and Lymphoid Neoplasm Database: C92.2, Atypical chronic myeloid leukemia, BCR/ABL-negative. Bethesda, MD: National Cancer Institute; 2024. Available from: https://seer.cancer.gov/seertools/hemelymph/